Pfizer gained a head start in December with the first U.S. emergency authorization of a COVID-19 vaccine, and has since jumped ahead of rivals.
Pfizer expects $33.5B in sales from COVID-19 vaccine with booster shot in works
© The Crystal Eyes
Pfizer gained a head start in December with the first U.S. emergency authorization of a COVID-19 vaccine, and has since jumped ahead of rivals.
© The Crystal Eyes